Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 10/20 | 0.53 |
| ▸ | F13A1 | P00488 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TGM1 | P22735 | 1/20 | 0.42 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | GSTO1 | P78417 | 4/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27477112 | 0.95 | TGM2 (0.49) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL6966255 | 0.81 | TGM2 (0.32) | TGM2EGFR | |
| SCHEMBL11512250 | 0.80 | ALDH1A1 (0.43) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL11465101 | 0.79 | SMN1; SMN2 (0.32) | TGM2PTPN1PTPN11 | |
| SCHEMBL9725165 | 0.78 | SMN1; SMN2 (0.44) | LMNA | |
| SCHEMBL7121801 | 0.77 | ALDH1A1 (0.36) | TGM2LMNA | |
| SCHEMBL11072074 | 0.76 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL6033544 | 0.76 | SMN1; SMN2 (0.38) | — | |
| SCHEMBL28043921 | 0.76 | — | — | |
| SCHEMBL55828 | 0.75 | GAA (0.42) | LMNAJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11897891-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-02-13 | — | — | US | claimed |
| WO-2021113479-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-06-10 | — | — | WO | claimed |
| WO-2021110142-A1 | SUBSTITUTED IMIDAZOLECARBOXAMIDE AS BRUTON'S TYROSINE KINASE INHIBITORS | HENAN NORMAL UNIVERSITY (CN) | 2021-06-10 | — | — | WO | claimed |
| US-20210171535-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-06-10 | — | — | US | claimed |
| EP-0601080-A1 | FILTERING COSMETIC COMPOSITION CONTAINING A LIPOSOLUBLE FILTER POLYMER WITH HYDROCARBONATED STRUCTURE AND A FILTER SILICONE. | OREAL (FR) | 1994-06-15 | — | — | EP | claimed |
| WO-1993004665-A1 | FILTERING COSMETIC COMPOSITION CONTAINING A LIPOSOLUBLE FILTER POLYMER WITH HYDROCARBONATED STRUCTURE AND A FILTER SILICONE | L'OREAL (FR) | 1993-03-18 | — | — | WO | claimed |
| US-4134768-A | Photographic uses of polyvinyl-phenylmercapto-tetrazoles | POLAROID CORPORATION (US) | 1979-01-16 | — | — | US | claimed |
| US-11897891-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-02-13 | — | — | US | disclosed |
| US-11548854-B2 | Heterocyclic compounds as pesticides | BAYER CROPSCIENCE AG (DE) | 2023-01-10 | — | — | US | disclosed |
| US-11332448-B2 | Heterocyclic compounds as pesticides | BAYER CROPSCIENCE AG (DE) | 2022-05-17 | — | — | US | disclosed |
| CN-107400092-B | Pyrimidine derivative, preparation method thereof and application thereof in medicine | 浙江海正药业股份有限公司 | 2021-08-24 | — | — | CN | disclosed |
| WO-2021132327-A1 | TETRAAZAPORPHYRIN COMPOUND, INK COMPOSITION, FILM, OPTICAL MATERIAL, OPTICAL FILM, DISPLAY SURFACE FILM, AND DISPLAY DEVICE | 大日本印刷株式会社 | 2021-07-01 | — | — | WO | disclosed |
| US-20210171535-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-06-10 | — | — | US | disclosed |
| US-6673905-B2 | FOR COVALENTLY LINKING CARBOHYDRATES AND PROTEINS UNDER NEUTRAL CONDITIONS, BY ATTACHING DOUBLE BONDS TO A CARRIER PROTEIN, AND ATTACHING A CONJUGATED DIENE TO A CARBOHYDRATE HAPTEN, THEN COUPLING; VACCINES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2004-01-06 | — | — | US | disclosed |
| US-20020068818-A1 | Conjugation of biomolecules using diels-alder cycloaddition | POZSGAY VINCE (US) | 2002-06-06 | — | — | US | disclosed |
| US-20020051788-A1 | For covalently linking carbohydrates and proteins under neutral conditions, by attaching double bonds to a carrier protein, and attaching a conjugated diene to a carbohydrate hapten, then coupling; vaccines | HEALTH AND HUMAN SERVICES, DEPARTMENT OF, GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, THE | 2002-05-02 | — | — | US | disclosed |
| US-4719248-A | BENZOTRIAZOLE UNSATURATED AMIDE | BAUSCH & LOMB INCORPORATED (US) | 1988-01-12 | — | — | US | disclosed |
| EP-0221630-A2 | Ultraviolet blocking agents for contact lenses | BAUSCH & LOMB INCORPORATED (US) | 1987-05-13 | — | — | EP | disclosed |
| US-4394487-A | GRAFTING AFFINE RESIDUE FOR NUCLEIC ACIDS ONTO POLYMERIC CARRIER | BOEHRINGER MANNHEIM GMBH (DE) | 1983-07-19 | — | — | US | disclosed |
| US-4335226-A | Adsorbent for the affinity-specific separation of macromolecular materials | BOEHRINGER MANNHEIM GMBH (DE) | 1982-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11897891-B2 | Tricyclic heterocycles as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | TGM2 175/4885F13A1 2860/4885LMNA 4496/4885 |
| US-11548854-B2 | Heterocyclic compounds as pesticides | DDT, ACHE, PTMS | TGM2 2859/4885F13A1 2934/4885LMNA 1612/4885 |
| US-20020068818-A1 | Conjugation of biomolecules using diels-alder cycloaddition | DERA, DCLRE1A, CD2BP2 | TGM2 873/4885F13A1 125/4885LMNA 2915/4885 |
| US-20210171535-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | TGM2 175/4885F13A1 2860/4885LMNA 4496/4885 |
| US-20020051788-A1 | For covalently linking carbohydrates and proteins under neutral conditions, by attaching double bonds to a carrier protein, and attaching a conjugated diene to a carbohydrate hapten, then coupling; vaccines | DCLRE1A, DERA, LY96 | TGM2 1210/4885F13A1 151/4885LMNA 1314/4885 |
| US-11332448-B2 | Heterocyclic compounds as pesticides | DDT, ACHE, PTMS | TGM2 2859/4885F13A1 2934/4885LMNA 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.